Company: Gilead Sciences
Posted by BiktarvyVet_SW · March 22, 2026
Tags: pipeline, general
Not going to lie, Biktarvy is a great product and for a while this territory practically ran itself.
But I've been thinking more about what happens when the generic window opens up.
The ID docs I call on are already asking questions.
Gilead has been good about staying ahead on resistance data and adherence profiles but the patent cliff is not that far away.
I worry the company is so dependent on Biktarvy that when it goes generic there's going to be a big contraction in the field force.
Not panicking but I'm not pretending the next three years are going to look like the last three either.
20 upvotes · 0 comments